Current Fungal Infection Reports

, Volume 13, Issue 2, pp 59–66 | Cite as

Non-Aspergillus Fungal Infections in Chronic Granulomatous Disease

  • Romain Guery
  • Benoît Pilmis
  • Bertrand Dunogue
  • Stéphane Blanche
  • Olivier Lortholary
  • Fanny LanternierEmail author
Pediatric Fungal Infections (D Corzo-Leon, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pediatric Fungal Infections


Purpose of Review

Management of Aspergillus infection in chronic granulomatous disease (CGD) patients remains a challenge even in new azoles era. However, epidemiology, diagnosis, and management of non-Aspergillus fungal infection (NAFI) in CGD setting are poorly described.

Recent Findings

NAFI appears to be rare in CGD patients and receiving antifungal prophylaxis. Clinical presentation is not specific of fungal species and patients often suffer from mild disease with prolonged course. While candidiasis and mucormycosis are also common in other immunocompromised population, infections caused by Phellinus tropicalis, Trichosporon inkin, and Rasamsonia argillacea have a unique predilection for CGD patients. Improved fungal identification with molecular methods allows description of new fungal species.


The available data for NAFI during CGD are limited and based on case reports and small series. Invasive tissue biopsies and advanced molecular methods are often required for diagnosis and guiding antifungal strategy in addition to a close collaboration between clinician, pathologist, and mycologist.


Invasive fungal disease Chronic granulomatous diseases Trichosporon inkin Phellinus tropicalis Rasamsonia argillacea Breakthrough infections Pediatric patients 



We thank Marie Desnos-Ollivier for her helpful comments.

Compliance with Ethical Standards

Conflict of Interest

Romain Guery reports participating in CME with support from Gilead outside the submitted work. Benoît Pilmis reports personal fees from MSD outside the submitted work. Fanny Lanternier reports personal fees from Gilead outside the submitted work. Bertrand Dunogue, Stéphane Blanche, and Olivier Lortholary declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–69.CrossRefGoogle Scholar
  2. 2.
    Beauté J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux M-E, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J. 2011;30:57–62.CrossRefGoogle Scholar
  3. 3.
    Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010;45:246–65.CrossRefGoogle Scholar
  4. 4.
    Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis. 2010;44:291–9.CrossRefGoogle Scholar
  5. 5.
    •• Blumental S, Mouy R, Mahlaoui N, Bougnoux M-E, Debré M, Beauté J, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis. 2011;53:e159–69. A French study conducted between 1984 and 2009 reporting characteristics and outcomes of 29 proven IFD in CGD patients. CrossRefGoogle Scholar
  6. 6.
    Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59:1462–70.CrossRefGoogle Scholar
  7. 7.
    Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60:1176–83.CrossRefGoogle Scholar
  8. 8.
    Desjardins A, Coignard-Biehler H, Mahlaoui N, Frange P, Bougnoux M-E, Blanche S, et al. Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections. Med Sci MS. 2012;28:963–9.Google Scholar
  9. 9.
    Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348:2416–22.CrossRefGoogle Scholar
  10. 10.
    Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR, et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. Clin Infect Dis. 2018;66:1678–86.CrossRefGoogle Scholar
  11. 11.
    van den Berg JM, van Koppen E, Åhlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4:e5234.CrossRefGoogle Scholar
  12. 12.
    Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J. 2015;45:1613–23.CrossRefGoogle Scholar
  13. 13.
    Dunogué B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, et al. Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France. Clin Infect Dis. 2017;64:767–75.CrossRefGoogle Scholar
  14. 14.
    •• Dotis J, Pana ZD, Roilides E. Non-Aspergillus fungal infections in chronic granulomatous disease. Mycoses. 2013;56:449–62. Excellent literature review of all cases of non-aspergillus fungal infections in CGD patients. CrossRefGoogle Scholar
  15. 15.
    •• Henriet S, Verweij PE, Holland SM, Warris A. Invasive fungal infections in patients with chronic granulomatous disease. Hot Top Infect Immun Child IX. Springer, New York, NY; 2013 [cited 2018 Feb 12]. p. 27–55. Available from: Extensive literature review of all cases of invasive fungal diseases in CGD published in the literature between 1970 and 2010.
  16. 16.
    Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol Orlando Fla. 2008;126:155–64.CrossRefGoogle Scholar
  17. 17.
    Estrada B, Mancao MY, Polski JM, Figarola MS. Candida lusitaniae and chronic granulomatous disease. Pediatr Infect Dis J. 2006;25:758–9.CrossRefGoogle Scholar
  18. 18.
    Kenney RT, Kwon-Chung KJ, Witebsky FG, Melnick DA, Malech HL, Gallin JI. Invasive infection with Sarcinosporon inkin in a patient with chronic granulomatous disease. Am J Clin Pathol. 1990;94:344–50.CrossRefGoogle Scholar
  19. 19.
    Mussa AY, Singh VK, Randhawa US, Khan ZU. Disseminated fatal trichosporonosis: first case due to Trichosporon inkin. J Med Mycol. 1998:196–9.Google Scholar
  20. 20.
    Piwoz JA, Stadtmauer GJ, Bottone EJ, Weitzman I, Shlasko E, Cummingham-Rundles C. Trichosporon inkin lung abscesses presenting as a penetrating chest wall mass. Pediatr Infect Dis J. 2000;19:1025–7.CrossRefGoogle Scholar
  21. 21.
    Wynne SM, Kwon-Chung KJ, Shea YR, Filie AC, Varma A, Lupo P, et al. Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease. J Allergy Clin Immunol. 2004;114:1418–24.CrossRefGoogle Scholar
  22. 22.
    Hajjar J, Restrepo A, Javeri H, Wiederhold NP, Papanastassiou AM, Patterson TF. Multiple brain abscesses caused by Trichosporon inkin in a patient with X-linked chronic granulomatous disease (CGD) successfully treated with antifungal therapy. J Clin Immunol. 2017;37:519–23.CrossRefGoogle Scholar
  23. 23.
    de Almeida Júnior JN, Hennequin C. Invasive Trichosporon infection: a systematic review on a re-emerging fungal pathogen. Front Microbiol [Internet]. 2016 [cited 2018 Jun 28];7. Available from:
  24. 24.
    Colombo AL, Padovan ACB, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev. 2011;24:682–700.CrossRefGoogle Scholar
  25. 25.
    Abinun M, Wright C, Gould K, Flood TJ, Cassidy J. absidia corymbifera in a patient with chronic granulomatous disease. Pediatr Infect Dis J. 2007;26:1167–8.CrossRefGoogle Scholar
  26. 26.
    Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723–7.CrossRefGoogle Scholar
  27. 27.
    Winstead M, Ozolek J, Nowalk A, Williams J, Vander Lugt M, Lin P. Disseminated Lichtheimia ramosa infection after hematopoietic stem cell transplantation in a child with chronic granulomatous disease. Pediatr Infect Dis J. 2017;36:1222–4.CrossRefGoogle Scholar
  28. 28.
    Al-Otaibi AM, Al-Shahrani DA, Al-Idrissi EM, Al-Abdely HM. Invasive mucormycosis in chronic granulomatous disease. Saudi Med J. 2016;37:567–9.CrossRefGoogle Scholar
  29. 29.
    Dekkers R, Verweij PE, Weemaes CM, Severijnen RS, van Krieken JH, et al. Gastrointestinal zygomycosis due to Rhizopus microsporus var. rhizopodiformis as a manifestation of chronic granulomatous disease. Med Mycol. 2008;46:491–4.CrossRefGoogle Scholar
  30. 30.
    Sutton DA, Thompson EH, Rinaldi MG, Iwen PC, Nakasone KK, Jung HS, et al. Identification and first report of Inonotus (Phellinus) tropicalis as an etiologic agent in a patient with chronic granulomatous disease. J Clin Microbiol. 2005;43:982–7.CrossRefGoogle Scholar
  31. 31.
    Nguyen DK, Davis CM, Chinen J, Vallejo JG, Noroski LM. Basidiomycetous Inonotus (Phellinus) tropicalis osteomyelitis in pediatric and adult X-linked chronic granulomatous disease. J Allergy Clin Immunol. 2009;123:S13.CrossRefGoogle Scholar
  32. 32.
    Davis CM, Noroski LM, Dishop MK, Sutton DA, Braverman RM, Paul ME, et al. Basidiomycetous fungal Inonotus tropicalis sacral osteomyelitis in X-linked chronic granulomatous disease. Pediatr Infect Dis J. 2007;26:655–6.CrossRefGoogle Scholar
  33. 33.
    Shigemura T, Nakazawa Y, Amano Y, Sudo A, Watanabe M, Kobayashi M, et al. Subcutaneous abscess due to the basidiomycete Phellinus mori in a patient with chronic granulomatous disease. Infection. 2015;43:371–5.CrossRefGoogle Scholar
  34. 34.
    De Ravin SS, Parta M, Sutton DA, Wickes BL, Thompson EH, Wiederhold NP, et al. Paravertebral mushroom: identification of a novel species of Phellinus as a human pathogen in chronic granulomatous disease. J Clin Microbiol. 2014;52:2726–9.CrossRefGoogle Scholar
  35. 35.
    Ramesh M, Resnick E, Hui Y, Maglione PJ, Mehta H, Kattan J, et al. Phellinus tropicalis abscesses in a patient with chronic granulomatous disease. J Clin Immunol. 2014;34:130–3.CrossRefGoogle Scholar
  36. 36.
    • Haidar G, Zerbe CS, Cheng M, Zelazny AM, Holland SM, Sheridan KR. Phellinus species: an emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease. Mycoses. 2017;60:155–60. A recent description of all published cases of Phellinus species infections in CGD. CrossRefGoogle Scholar
  37. 37.
    DeRavin S. Invasive basidiomycetous Phellinus/Inonotus spp. infections in chronic granulomatous disease [Internet]. Boston, Massachusetts; 2014 [cited 2018 Mar 4]. Available from:
  38. 38.
    Williamson D, Pandey S, Taylor S, Rogers K, Storey L, Marshall MR, et al. A case of infection caused by the basidiomycete Phellinus undulatus. J Med Microbiol. 2011;60:256–8.CrossRefGoogle Scholar
  39. 39.
    Al AF-C et. Inonotosis in patient with hematologic malignancy - Volume 24, Number 1—January 2018 - Emerging Infectious Disease journal - CDC. [cited 2018 Mar 4]; Available from:
  40. 40.
    Houbraken J, Giraud S, Meijer M, Bertout S, Frisvad JC, Meis JF, et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol. 2013;51:22–30.CrossRefGoogle Scholar
  41. 41.
    Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.CrossRefGoogle Scholar
  42. 42.
    • De Ravin SS, Challipalli M, Anderson V, Shea YR, Marciano B, Hilligoss D, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis. 2011;52:e136–43. The first description of Rasamsonia argillacea infections in CGD which are associated with poor outcomes. CrossRefGoogle Scholar
  43. 43.
    Valentin T, Neumeister P, Pichler M, Rohn A, Koidl C, Haas D, et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant. 2012;47:734–6.CrossRefGoogle Scholar
  44. 44.
    Machouart M, Garcia-Hermoso D, Rivier A, Hassouni N, Catherinot E, Salmon A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis▿. J Clin Microbiol. 2011;49:1681–3.CrossRefGoogle Scholar
  45. 45.
    Ishiwada N, Takeshita K, Yaguchi T, Nagasawa K, Takeuchi N, Hishiki H, et al. The first case of Invasive mixed-Mold infections due to Emericella nidulans var. echinulata and Rasamsonia piperina in a patient with chronic granulomatous disease. Mycopathologia. 2016;181:305–9.CrossRefGoogle Scholar
  46. 46.
    Steinmann J, Dittmer S, Houbraken J, Buer J, Rath P-M. In vitro activity of Isavuconazole against Rasamsonia species. Antimicrob Agents Chemother. 2016;60:6890–1.CrossRefGoogle Scholar
  47. 47.
    Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.CrossRefGoogle Scholar
  48. 48.
    Gompels MM, Bethune CA, Jackson G, Spickett GP. Scedosporium apiospermum in chronic granulomatous disease treated with an HLA matched bone marrow transplant. J Clin Pathol. 2002;55:784–6.CrossRefGoogle Scholar
  49. 49.
    Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39:87–90.CrossRefGoogle Scholar
  50. 50.
    Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis. 1998;27:1437–41.CrossRefGoogle Scholar
  51. 51.
    Phillips P, Forbes JC, Speert DP. Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. Pediatr Infect Dis J. 1991;10:536–9.CrossRefGoogle Scholar
  52. 52.
    Meletiadis J, Mouton JW, Meis JFGM, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106–17.CrossRefGoogle Scholar
  53. 53.
    Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses. 2003;46:233–6.CrossRefGoogle Scholar
  54. 54.
    Vinh DC, Freeman AF, Shea YR, Malech HL, Abinun M, Weinberg GA, et al. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol. 2009;123:1411–3.CrossRefGoogle Scholar
  55. 55.
    Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-± blockade in chronic granulomatous disease—related colitis. Clin Infect Dis. 2010;51:1429–34.CrossRefGoogle Scholar
  56. 56.
    Holland SM, Shea YR, Kwon-Chung J. Regarding “Trichosporon pullulans infection in 2 patients with chronic granulomatous disease”. J Allergy Clin Immunol. 2004;114:205–6 author reply 206.CrossRefGoogle Scholar
  57. 57.
    Singh PK, Kathuria S, Agarwal K, Gaur SN, Meis JF, Chowdhary A. Clinical significance and molecular characterization of nonsporulating molds isolated from the respiratory tracts of bronchopulmonary mycosis patients with special reference to basidiomycetes. J Clin Microbiol. 2013;51:3331–7.CrossRefGoogle Scholar
  58. 58.
    Romanelli AM, Sutton DA, Thompson EH, Rinaldi MG, Wickes BL. Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol. 2010;48:741–52.CrossRefGoogle Scholar
  59. 59.
    Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol. 2000;38:3900–1.Google Scholar
  60. 60.
    Guery R, Subran B, Lefevre A, Lanternier F. Kinetics of radiological response of thoracic invasive fungal disease in chronic granulomatous disease. J Clin Immunol. 2017;37:623–5.CrossRefGoogle Scholar
  61. 61.
    Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51–61.CrossRefGoogle Scholar
  62. 62.
    Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. 2005;40:1684–8.CrossRefGoogle Scholar
  63. 63.
    Frisch S, Askari SK, Beaty SR, Burkemper CN. X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/ photoaging reaction. J Drugs Dermatol. 2010;9:562–4.Google Scholar
  64. 64.
    Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015;72:314–20.CrossRefGoogle Scholar
  65. 65.
    Epaulard O, Villier C, Ravaud P, Chosidow O, Blanche S, Mamzer-Bruneel M-F, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. 2013;57:e182–8.CrossRefGoogle Scholar
  66. 66.
    Moon WJ, Scheller EL, Suneja A, Livermore JA, Malani AN, Moudgal V, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis. 2014;59:1237–45.CrossRefGoogle Scholar
  67. 67.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet Lond Engl. 2016;387:760–9.CrossRefGoogle Scholar
  68. 68.
    Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–37.CrossRefGoogle Scholar
  69. 69.
    • Denis J, Ledoux M-P, Nivoix Y, Herbrecht R. Isavuconazole: a new broad-spectrum azole. Part 1: in vitro activity. J Mycol Médicale. 2018;28:8–14. A comprehensive review of in-vitro activity of Isavuconazole showing potential for treating infection with rare molds. CrossRefGoogle Scholar
  70. 70.
    Yoshihara S, Ikemoto J, Fujimori Y. Update on granulocyte transfusions: accumulation of promising data, but still lack of decisive evidence. Curr Opin Hematol. 2016;23:55–60.CrossRefGoogle Scholar
  71. 71.
    Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. Transfusion (Paris). 1996;36:1009–15.CrossRefGoogle Scholar
  72. 72.
    •• Marciano BE, Allen ES, Conry-Cantilena C, Kristosturyan E, Klein HG, Fleisher TA, et al. Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: the NIH experience. J Allergy Clin Immunol. 2017;140:622–5. A recent retrospective study from the NIH showing efficacy of granulocyte transfusions in CGD patients with intractable fungal infections. CrossRefGoogle Scholar
  73. 73.
    Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401–9.CrossRefGoogle Scholar
  74. 74.
    Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, et al. Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD - importance of timing. Curr Gene Ther. 2015;15:416–27.CrossRefGoogle Scholar
  75. 75.
    Parta M, Hilligoss D, Kelly C, Kwatemaa N, Theobald N, Malech H, et al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. J Clin Immunol. 2015;35:675–80.CrossRefGoogle Scholar
  76. 76.
    Sastry J, Kakakios A, Tugwell H, Shaw PJ. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer. 2006;47:327–9.CrossRefGoogle Scholar
  77. 77.
    Ozsahin H, von Planta M, Müller I, Steinert HC, Nadal D, Lauener R, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood. 1998;92:2719–24.Google Scholar
  78. 78.
    Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet Lond Engl. 2014;383:436–48.CrossRefGoogle Scholar
  79. 79.
    Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34:2543–57.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Romain Guery
    • 1
  • Benoît Pilmis
    • 1
    • 2
  • Bertrand Dunogue
    • 3
  • Stéphane Blanche
    • 4
  • Olivier Lortholary
    • 1
    • 5
  • Fanny Lanternier
    • 1
    • 5
    Email author
  1. 1.Sorbonne Paris Cité, Infectious Diseases Unit, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Imagine InstituteParis Descartes UniversityParisFrance
  2. 2.Antimicrobial stewardship team, Microbiology UnitGroupe Hospitalier Paris Saint JosephParisFrance
  3. 3.Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital CochinAssistance Publique-Hôpitaux de Paris (AP-HP)ParisFrance
  4. 4.Pediatric Immuno-Haematology and Rheumatology Unit, Assistance Publique-Hôpitaux de Paris (AP-HP)Necker Enfants Malades University HospitalParisFrance
  5. 5.Institut Pasteur, CNRS, Centre National de Référence Mycoses Invasives et AntifongiquesUnité de Mycologie Moléculaire, UMR 2000ParisFrance

Personalised recommendations